In a filing, Aldeyra Therapeutics Inc revealed its 10% Owner PERCEPTIVE ADVISORS LLC unloaded Company’s shares for reported $4.83 million on Apr 03 ’25. In the deal valued at $1.42 per share,3,400,000 shares were sold. As a result of this transaction, PERCEPTIVE ADVISORS LLC now holds 5,875,851 shares worth roughly $28.26 million.
Then, Machatha Stephen sold 16,041 shares, generating $75,975 in total proceeds. Upon selling the shares at $4.74, the Chief Development Officer now owns 236,771 shares.
Before that, Greenberg Bruce sold 10,834 shares. Aldeyra Therapeutics Inc shares valued at $51,313 were divested by the insider at a price of $4.74 per share. As a result of the transaction, Greenberg Bruce now holds 126,382 shares, worth roughly $0.61 million.
Oppenheimer upgraded its Aldeyra Therapeutics Inc [ALDX] rating to an Outperform from a a Perform in a research note published recently. H.C. Wainwright started covering the stock on February 08, 2021. It rated ALDX as “a Buy”.
Price Performance Review of ALDX
On Friday, Aldeyra Therapeutics Inc [NASDAQ:ALDX] saw its stock fall -3.61% to $4.81. Over the last five days, the stock has lost -6.96%. Aldeyra Therapeutics Inc shares have risen nearly 21.77% since the year began. Nevertheless, the stocks have fallen -3.61% over the past one year. While a 52-week high of $7.20 was reached on 03/12/25, a 52-week low of $1.14 was recorded on 04/03/25.
Levels Of Support And Resistance For ALDX Stock
The 24-hour chart illustrates a support level at 4.39, which if violated will result in even more drops to 3.96. On the upside, there is a resistance level at 5.08. A further resistance level may holdings at 5.34.
How much short interest is there in Aldeyra Therapeutics Inc?
A steep rise in short interest was recorded in Aldeyra Therapeutics Inc stocks on 2025-07-15, growing by 0.13 million shares to a total of 4.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 4.49 million shares. There was a rise of 2.9%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 16, 2020 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
